>so the time for DNA/BIIB's product to become generic is not that long<
I see now that you were referring to the 2014 date specified in today’s GTC PR. (I had previously assumed you were giving your own assessment of the CD20 patent life.)
The sentence of consequence in the PR is:
“The existing relevant CD20 antibody patents will expire by 2014.”
However, the word existing changes the complexion of the sentence substantially. As noted in #msg-21771786, BIIB says in its SEC filings that key CD20 patents for which it has applied have not yet issued. Moreover, if you search the patent applications that relate to therapeutic CD20 mAbs on the USPTO website, there are a great many hits.
In other words, despite the 2014 date in GTC’s PR, I highly doubt that the patent landscape for mAbs targeting CD20 is as simple as today’s PR makes it seem. Regards, Dew
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.